BioWorld

Jan. 28, 2002

View Archived Issues

AltaRex Plans U.S. Filing Despite Mixed Results Of OvaRex Trials

Despite inconsistent results in Phase IIb trials, Canadian company AltaRex Corp. intends this year to file a rolling biologics license application for its late-stage ovarian cancer drug, OvaRex. Read More

Trimeris Raising $41M Privately As It Eyes NDA For HIV Drug

Read More

Hunt For Signs Of Life On Mars Gets Boost From Live Archaea Deep Under Idaho Hot Springs

Read More

Intradigm, DirectGene Team Up To Develop Cancer Therapeutics

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More